98 related articles for article (PubMed ID: 3717195)
21. Plasma prolactin in the rat during suckling without prior separation from pups.
Mattheij JA; Swarts HJ; van Mourik S
Acta Endocrinol (Copenh); 1985 Apr; 108(4):468-74. PubMed ID: 3993313
[TBL] [Abstract][Full Text] [Related]
22. Comparison of metoclopramide with other dynamic tests of prolactin secretion.
Sowers JR; McCallum RW; Hershman JM; Carlson HE; Sturdevant RA; Meyer N
J Clin Endocrinol Metab; 1976 Sep; 43(3):679-81. PubMed ID: 821965
[TBL] [Abstract][Full Text] [Related]
23. Twenty-four-hour prolactin profiles in normal and disease states: failure of thyroxine to modify prolactin secretion.
Malarkey WB; Beck P
J Clin Endocrinol Metab; 1975 Apr; 40(4):708-12. PubMed ID: 1168655
[TBL] [Abstract][Full Text] [Related]
24. A detailed characterization of prolactin secretion patterns during daylight in individual cycling and pseudopregnant rats.
Wiersma J
Neuroendocrinology; 1981 Nov; 33(5):288-94. PubMed ID: 7197760
[TBL] [Abstract][Full Text] [Related]
25. Clinical pharmacokinetic studies of perphenazine.
Eggert Hansen C; Rosted Christensen T; Elley J; Bolvig Hansen L; Kragh-Sorensen P; Larsen NE; Naestoft J; Hvidberg EF
Br J Clin Pharmacol; 1976 Oct; 3(5):915-23. PubMed ID: 973987
[TBL] [Abstract][Full Text] [Related]
26. Dynamics of prolactin secretion in patients with hypopituitarism and pituitary macroadenomas.
Arafah BM; Nekl KE; Gold RS; Selman WR
J Clin Endocrinol Metab; 1995 Dec; 80(12):3507-12. PubMed ID: 8530591
[TBL] [Abstract][Full Text] [Related]
27. Prolactin responses to haloperidol in normal young women.
Asnis GM; Sachar EJ; Langer G; Tabrizi MA; Nathan RS; Halpern FS; Halbreich U
Psychoneuroendocrinology; 1988; 13(6):515-20. PubMed ID: 3237947
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of apomorphine-induced hypermotility in rats by chlorpromazine, perphenazine, thioridazine and melperone.
Lassen JB
Acta Pharmacol Toxicol (Copenh); 1977 Mar; 40(3):418-29. PubMed ID: 576565
[TBL] [Abstract][Full Text] [Related]
29. The effect of angiotensin-converting enzyme inhibition on prolactin responses in normal and hyperprolactinemic subjects.
Anderson PW; Malarkey WB; Salk J; Kletsky OA; Hsueh WA
J Clin Endocrinol Metab; 1989 Sep; 69(3):518-22. PubMed ID: 2503532
[TBL] [Abstract][Full Text] [Related]
30. Plasma levels of perphenazine (Trilafon) related to development of extrapyramidal side effects.
Hansen LB; Larsen NE; Vestergård P
Psychopharmacology (Berl); 1981; 74(4):306-9. PubMed ID: 6794071
[TBL] [Abstract][Full Text] [Related]
31. Plasma prolactin responses to acute changes in central blood volume in man.
Mills DE; Robertshaw D
Horm Res; 1983; 18(4):153-9. PubMed ID: 6642422
[TBL] [Abstract][Full Text] [Related]
32. CYP2D6 genotype in relation to perphenazine concentration and pituitary pharmacodynamic tissue sensitivity in Asians: CYP2D6-serotonin-dopamine crosstalk revisited.
Ozdemir V; Bertilsson L; Miura J; Carpenter E; Reist C; Harper P; Widén J; Svensson JO; Albers LJ; Kennedy JL; Endrenyi L; Kalow W
Pharmacogenet Genomics; 2007 May; 17(5):339-47. PubMed ID: 17429316
[TBL] [Abstract][Full Text] [Related]
33. Effects of dietary lipid saturation on prolactin secretion, carcinogen metabolism and mammary carcinogenesis in rats.
Clinton SK; Mulloy AL; Visek WJ
J Nutr; 1984 Sep; 114(9):1630-9. PubMed ID: 6432976
[TBL] [Abstract][Full Text] [Related]
34. Angiotensin II stimulates prolactin release in the rhesus monkey.
Dufy-Barbe L; Rodriguez F; Arsaut J; Verrier D; Vincent JD
Neuroendocrinology; 1982 Oct; 35(4):242-7. PubMed ID: 7145020
[TBL] [Abstract][Full Text] [Related]
35. Prolactin response to N3im-methyl-thyrotropin releasing hormone in euthyroid subjects.
Sowers JR; Hershman JM; Carlson HE; Pekary E; Nair MG; Baugh CM
J Clin Endocrinol Metab; 1976 Oct; 43(4):749-55. PubMed ID: 824297
[TBL] [Abstract][Full Text] [Related]
36. Prolactin suppression by (-) delta-9-tetrahydrocannabinol (THC): involvement of serotonergic and dopaminergic pathways.
Kramer J; Ben-David M
Endocrinology; 1978 Aug; 103(2):452-7. PubMed ID: 744093
[TBL] [Abstract][Full Text] [Related]
37. Gonadotropin-releasing hormone antagonists attenuate estrogen/progesterone-induced hyperprolactinemia in monkeys.
Olive DL; Sabella V; Riehl RM; Schenken RS; Moreno A
Fertil Steril; 1989 Jun; 51(6):1040-5. PubMed ID: 2656304
[TBL] [Abstract][Full Text] [Related]
38. TRANQUILLIZING AND HYPOTENSIVE ACTIVITIES OF TWELVE PHENOTHIAZINES.
BHARGAVA KP; CHANDRA OM
Br J Pharmacol Chemother; 1964 Feb; 22(1):154-61. PubMed ID: 14126045
[TBL] [Abstract][Full Text] [Related]
39. Comparison of the effects of contraceptive steroid formulations containing two doses of estrogen on pituitary function.
Scott JZ; Kletzky OA; Brenner PF; Mishell DR
Fertil Steril; 1978 Aug; 30(2):141-5. PubMed ID: 98356
[TBL] [Abstract][Full Text] [Related]
40. Prolactin and growth hormone secretion in chemically induced and genetically obese mice.
Sinha YN; Salocks CB; Vanderlaan WP
Endocrinology; 1975 Dec; 97(6):1386-93. PubMed ID: 1107014
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
